MCID: VSC008
MIFTS: 36

Vascular Hemostatic Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Hemostatic Disease

MalaCards integrated aliases for Vascular Hemostatic Disease:

Name: Vascular Hemostatic Disease 12 15
Vascular Hemostatic Disorders 73
Hemostatic Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:484
MeSH 44 D020141
SNOMED-CT 68 21112004
UMLS 73 C0600502

Summaries for Vascular Hemostatic Disease

MalaCards based summary : Vascular Hemostatic Disease, also known as vascular hemostatic disorders, is related to thrombophilia due to activated protein c resistance and thrombophilia due to protein c deficiency, autosomal dominant. An important gene associated with Vascular Hemostatic Disease is KRIT1 (KRIT1, Ankyrin Repeat Containing). The drugs rituximab and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Related Diseases for Vascular Hemostatic Disease

Diseases related to Vascular Hemostatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 10.9
2 thrombophilia due to protein c deficiency, autosomal dominant 10.8
3 thrombophilia, x-linked, due to factor ix defect 10.8
4 thrombophilia due to protein c deficiency, autosomal recessive 10.8
5 thrombophilia due to protein s deficiency, autosomal dominant 10.8
6 heparin cofactor ii deficiency 10.8
7 thrombophilia due to histidine-rich glycoprotein deficiency 10.8
8 antithrombin iii deficiency 10.8
9 protein z deficiency 10.8
10 thrombophilia due to thrombomodulin defect 10.8
11 intracranial structure hemangioma 10.4 KRIT1 SNRPB
12 brain angioma 10.4 KRIT1 SNRPB
13 cerebral angioma 10.3 KRIT1 SNRPB
14 hemangioma of intra-abdominal structure 10.2 HBA1 KRIT1
15 hemangioma of liver 9.9 F2 HBA1 KRIT1
16 sickle cell anemia 9.8 F2 HBA1
17 hemangioma 9.7 CCM2 KRIT1
18 arteries, anomalies of 9.6
19 rheumatoid arthritis 9.6
20 anemia, autoimmune hemolytic 9.6
21 aging 9.6
22 myocardial infarction 9.6
23 graft-versus-host disease 9.6
24 arthritis 9.6
25 hemolytic anemia 9.6
26 thrombocytopenia 9.6
27 peripheral artery disease 9.6
28 myeloproliferative neoplasm 9.6
29 chronic graft versus host disease 9.6
30 pituitary tumors 9.6
31 human venous malformation 9.4 CCM2 KRIT1 PDCD10
32 cavernous malformation 9.4 CCM2 KRIT1 PDCD10
33 klippel-trenaunay-weber syndrome 9.3 CCM2 KRIT1 PDCD10
34 venous malformations, multiple cutaneous and mucosal 9.3 CCM2 KRIT1 PDCD10
35 cerebral cavernous malformations 9.3 CCM2 KRIT1 PDCD10
36 central nervous system hemangioma 9.1 CCM2 KRIT1 PDCD10 SNRPB
37 cerebral cavernous malformations 3 9.1 CCM2 KRIT1 PDCD10 SNRPB
38 cerebral cavernous malformations 2 9.1 CCM2 KRIT1 PDCD10 SNRPB
39 cell type benign neoplasm 9.0 CCM2 KRIT1 PDCD10 SNRPB
40 cavernous hemangioma 8.8 CCM2 F2 KRIT1 PDCD10

Graphical network of the top 20 diseases related to Vascular Hemostatic Disease:



Diseases related to Vascular Hemostatic Disease

Symptoms & Phenotypes for Vascular Hemostatic Disease

Drugs & Therapeutics for Vascular Hemostatic Disease

Drugs for Vascular Hemostatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 778)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
4
Menthol Approved Phase 4,Phase 1,Not Applicable 2216-51-5 16666
5
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
6
Warfarin Approved Phase 4,Phase 3,Phase 1,Not Applicable 81-81-2 6691 54678486
7
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
8
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
9
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
10
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
11
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
13
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 1197-18-8 5526
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
17
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
18
Apixaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 503612-47-3 10182969
19
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
20
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 4053 460612
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
22
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
23
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
24
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
25
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
26
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
27
Phentolamine Approved Phase 4 50-60-2 5775
28
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
29 fluindione Approved, Investigational Phase 4 957-56-2
30
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
31
Celiprolol Approved, Investigational Phase 4 56980-93-9
32
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
33
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
34
Phenindione Approved, Investigational Phase 4 83-12-5 4760
35 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
36
Enoxaparin Approved Phase 4,Phase 2 9005-49-6 772
37
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-45-1 5951
38
Menadione Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 58-27-5 4055
39
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
40
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 84-80-0 4812 5284607
41
Pirarubicin Investigational Phase 4 72496-41-4
42
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
43 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
46 Factor VIII Phase 4,Phase 3,Phase 2,Phase 1
47 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Fibrinolytic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2790)
# Name Status NCT ID Phase Drugs
1 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
2 Treatment of Coagulopathy Trauma-induced Guided by Thromboelastography in Politrauma Patients. Unknown status NCT02864875 Phase 4 Fibrinogen concentrate
3 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
4 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
5 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
6 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
7 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
8 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
9 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes Completed NCT00738023 Phase 4 Rosiglitazone;Normal saline 0.9%;Intralipid 20%
10 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
11 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
12 Octaplas Pediatric Plasma Replacement Trial Completed NCT02050841 Phase 4
13 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
14 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
15 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
16 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
17 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
18 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
19 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
20 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
21 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
22 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
23 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
24 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
25 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
26 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
27 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
28 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
29 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
30 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
31 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
32 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
33 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
34 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
35 Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
36 Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Recruiting NCT02774317 Phase 4
37 Human Fibrinogen Concentrate in Pediatric Cardiac Surgery Recruiting NCT02822599 Phase 4 RiaStAP;Saline
38 Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal Recruiting NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
39 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period Recruiting NCT03449342 Phase 4 turoctocog alfa
40 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
41 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
42 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
43 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
44 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
45 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
46 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
47 Intranasal Bevacizumab for HHT-Related Epistaxis Recruiting NCT02389959 Phase 4 Bevacizumab;Placebo (Saline)
48 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
49 Clinical and Economic Implications of Genetic Testing for Warfarin Management Active, not recruiting NCT00964353 Phase 4 Warfarin
50 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide

Search NIH Clinical Center for Vascular Hemostatic Disease

Cochrane evidence based reviews: hemostatic disorders

Genetic Tests for Vascular Hemostatic Disease

Anatomical Context for Vascular Hemostatic Disease

MalaCards organs/tissues related to Vascular Hemostatic Disease:

41
Bone, Bone Marrow, T Cells, B Cells, Testes, Kidney, Liver

Publications for Vascular Hemostatic Disease

Articles related to Vascular Hemostatic Disease:

(show all 13)
# Title Authors Year
1
Hemostatic Disorders in Hormonally Active Pituitary Tumors. ( 26285071 )
2015
2
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. ( 24951423 )
2014
3
[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]. ( 21574459 )
2011
4
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. ( 19684626 )
2009
5
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. ( 19012190 )
2008
6
Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. ( 18001734 )
2008
7
Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. ( 12818247 )
2003
8
[An inherited hemostatic disorder as the cause of menorrhagia]. ( 11938574 )
2002
9
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]. ( 9499627 )
1998
10
[Recurrent epistaxis in children as an indicator of hemostatic disorders]. ( 9949588 )
1998
11
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. ( 8522567 )
1995
12
[The Willebrand factor in the diagnosis of hemostatic disorders in patients with rheumatoid arthritis]. ( 1710721 )
1991
13
[Characteristics of hemostatic disorders in septic shock in children]. ( 2396772 )
1990

Variations for Vascular Hemostatic Disease

Expression for Vascular Hemostatic Disease

Search GEO for disease gene expression data for Vascular Hemostatic Disease.

Pathways for Vascular Hemostatic Disease

GO Terms for Vascular Hemostatic Disease

Cellular components related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.43 C1QC CD2AP F2 HBA1 PDCD10 SNRPB
2 blood microparticle GO:0072562 8.8 C1QC F2 HBA1

Biological processes related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hydrogen peroxide GO:0042542 9.16 HBA1 PDCD10
2 positive regulation of protein localization to nucleus GO:1900182 8.96 CD2AP F2
3 regulation of complement activation GO:0030449 8.8 C1QC CFHR4 F2

Sources for Vascular Hemostatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....